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Adapted from UKPDS 34. Lancet 1998; 352:854–865.
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UKPDS: time-dependent reduction in 














UKPDS 49. JAMA 1999; 281:2005–2012.
Background: Largest head-to-head, double-blind study of metformin, 
glyburide and rosiglitazone (N = 4,360)
Primary objective: To compare the durability of glycemic control using 
rosiglitazone versus metformin or glyburide as initial 
monotherapy in patients with recently diagnosed 
type 2 diabetes
Design: Double-blind, randomized, controlled trial
Inclusion criteria: Type 2 diabetes ≤ 3 years, drug-naive, male and female, 
aged 30–75 years, FPG 126–180 mg/dl (7–10 mmol/l)
Exclusion criteria: Previous use of glucose-lowering therapy, women of 
child-bearing potential, significant hepatic disease, renal 
impairment, unstable or severe angina, known CHF 
(NYHA Class I–IV), uncontrolled hypertension
Treatment duration: Treatment period: 4 to 6 years
Median duration of treatment: 4 years (rosiglitazone and 
metformin); 3.3 years (glyburide)
Interventions: Rosiglitazone, metformin, glyburide
ADOPT: overview
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.
ADOPT: study endpoints
Primary outcome: monotherapy failure
• FPG > 180 mg/dl (> 10 mmol/l)
– After at least 6 weeks of treatment at maximum tolerated dose, 
confirmed on repeat testing
OR
• Independent, masked adjudication for subjects with:
– No repeat testing, withdrawal due to insufficient therapeutic effect, 
initiation of non-study glucose-lowering therapy
Secondary outcomes:
• Confirmed FPG > 140 mg/dl (> 7.8 mmol/l)
• Remaining on monotherapy with HbA1c < 7%
• Longitudinal collection of glycemic measures, anthropometrics, insulin 
sensitivity and β-cell function
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.
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Age, years 56.3 ± 10.0 57.9 ± 9.9 56.4 ± 10.2
Male 56% 59% 58%
Caucasian 87% 89% 89%
North America 52% 52% 53%
Europe 48% 48% 47%
Time since 
diabetes diagnosis
< 1 year 45% 46% 44%
1 2 years 52% 50% 52%
> 2 3 years 3% 4% 4%
P > 0.05 for all comparisons
ADOPT: baseline characteristics
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.







Hypertension treatment 51% 51% 52%
Lipid-lowering treatment 26% 26% 26%
History of CVD 16% 19% 17%
BMI (kg/m2) 32.2 ± 6.7 32.1 ± 6.1 32.2 ± 6.3
FPG (mg/dl) 152 ± 26 151 ± 26 152 ± 27
HbA1c (%) 7.4 ± 0.9 7.4 ± 0.9 7.4 ± 0.9
P > 0.05 for all comparisons
ADOPT: baseline characteristics (cont’d)
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.
http://www.adopt-study.org/slides.php. Accessed December 2006.
ADOPT: cumulative incidence of








































32% risk reduction, P < 0.001
Rosiglitazone vs glyburide
63% risk reduction, P < 0.001
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.
http://www.adopt-study.org/slides.php. Accessed December 2006.
ADOPT: cumulative incidence of FPG > 140 mg/dl 
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36% risk reduction, P = 0.002
Rosiglitazone vs glyburide
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ADOPT: FPG over time
Rosiglitazone vs metformin
9.8 ( 12.7 to 7.0), P < 0.001
Rosiglitazone vs glyburide
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Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.
http://www.adopt-study.org/slides.php. Accessed December 2006.
ADOPT: HbA1c over time













0.13 ( 0.22 to 0.05), P = 0.002
Rosiglitazone vs glyburide
0.42 ( 0.50 to 0.33), P < 0.001
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.
http://www.adopt-study.org/slides.php. Accessed December 2006.














12.6%, P < 0.001
Rosiglitazone vs glyburide




Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.
http://www.adopt-study.org/slides.php. Accessed December 2006.
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ADOPT: -cell function over time
Rosiglitazone vs metformin
5.8%, P = 0.003
Rosiglitazone vs glyburide
















Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.
http://www.adopt-study.org/slides.php. Accessed December 2006.
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Rosiglitazone vs metformin
6.9 (6.3 to 7.4), P < 0.001
Rosiglitazone vs glyburide
2.5 (2.0 to 3.1), P < 0.001
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.
http://www.adopt-study.org/slides.php. Accessed December 2006.

















Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.
http://www.adopt-study.org/slides.php. Accessed December 2006.
ADOPT: waist-hip ratio over time
Rosiglitazone vs metformin
0.008 ( 0.016 to 0.001), P = 0.03
Rosiglitazone vs glyburide















































P < 0.05 vs rosiglitazone
ADOPT: lipids
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.















ALT > 3x ULN, n (%) 14 (1.0%) 16 (1.1%) 11 (0.8%)









below ref. range, n (%)
41 (2.8%) 22 (1.5%) 14 (1.0%)
P< 0.05 vs rosiglitazone
ADOPT: laboratory measures
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.










Patients with event(s) 1,338 (92) 1,341 (92) 1,321 (92)
Hospitalization from any 
cause
Patients 169 (12) 172 (12) 150 (10)
Events 251 267 203
Death from any cause 34 (2.3) 31 (2.1) 31 (2.2)
ADOPT: adverse events, hospitalizations 
and deaths
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.










Cardiovascular disease 49 (3.4) 46 (3.2) 26 (1.8)
Myocardial infarction
Fatal 2 (0.1) 2 (0.1) 3 (0.2)
Non-fatal 22 (1.5) 18 (1.2) 11 (0.8)
Congestive heart failure 12 (0.8) 12 (0.8) 3 (0.2)
Stroke 13 (0.9) 17 (1.2) 12 (0.8)
Peripheral vascular 
disease
7 (0.5) 6 (0.4) 4 (0.3)
P < 0.05 vs rosiglitazone
ADOPT: vascular serious adverse events, 
investigator reported
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.










Adverse events 22 (1.5) 19 (1.3) 9 (0.6)
Serious adverse events 12 (0.8) 12 (0.8) 3 (0.2)
Cardiologist review 9 (0.6) 8 (0.6) 4 (0.3)
P < 0.05 vs rosiglitazone
ADOPT: congestive heart failure
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.










Gastrointestinal 335 (23) 557 (38) 316 (22)
Weight gain 100 (7) 18 (1) 47 (3)
Hypoglycemia 142 (10) 168 (12) 557 (39)
Edema 205 (14) 104 (7) 123 (9)
P < 0.05 vs rosiglitazone
ADOPT: other adverse events
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.










Men 32 (4.0) 29 (3.4) 28 (3.4)
Women 60 (9.3) 30 (5.1) 21 (3.5)
Upper limb 22 (3.4) 10 (1.7) 9 (1.5)
Lower limb 36 (5.6) 18 (3.1) 8 (1.3)
Hip 2 (0.3) 2 (0.3) 0 (0.0)
Spine 1 (0.2) 1 (0.2) 1 (0.2)
P < 0.05 vs rosiglitazone
ADOPT: fractures
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.
http://www.adopt-study.org/slides.php. Accessed December 2006.
• Initial treatment of type 2 diabetes with rosiglitazone slowed 
progression of hyperglycemia compared to metformin or 
glyburide as assessed by FPG > 180 mg/dl and > 140 mg/dl
• 32% risk reduction of monotherapy failure vs metformin
(P < 0.001) (FPG > 180 mg/dl)
– Effect was more pronounced in older patients ( 50 years) 
and more obese patients (waist circumference > 110 cm)
• 63% risk reduction of monotherapy failure vs glyburide 
(P < 0.001) (FPG > 180 mg/dl)
– Effect was more pronounced in older patients ( 50 years), 
women and more obese patients (BMI 30 kg/m2)
• Rosiglitazone was associated with significant improvements in 
insulin sensitivity and a reduced rate of loss of -cell function vs 
metformin and glyburide
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.
http://www.adopt-study.org/slides.php. Accessed December 2006.
ADOPT: summary of findings
• Rosiglitazone was associated with weight gain and 
edema, and in women, fractures
• Metformin was associated with adverse 
gastrointestinal events
• Glyburide was associated with hypoglycemia and 
weight gain
• Rosiglitazone and metformin had a similar risk of 
cardiovascular events. Glyburide had a lower risk of 
cardiovascular events than rosiglitazone
ADOPT: summary of findings (cont’d)
Kahn SE, et al. N Engl J Med 2006; 355:2427–2443.
http://www.adopt-study.org/slides.php. Accessed December 2006.
CHALLENGE OF DISTINGUISHING TYPE 2 FROM TYPE 1
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